Aimed Alliance Comments on Oregon’s PDAB Process
On February 25, 2024, Aimed Alliance sent a letter to the Oregon Prescription Drug Affordability Board regarding its current patient…
Browsing: Drug Pricing: Policy Activity
Study Finds 340B Hospitals Significantly Markup Infusion Drugs
A recent study published in the New England Journal of Medicine examined the pricing practices of hospitals participating in the…
Senators Seek Input on Draft 340B Reform Bill
The Senate 340B Working Group is soliciting additional stakeholder input on key longstanding issues surrounding the Medicare 340B program. The…
Senate Pushes for FTC Progress in PBM Investigation
Senate Commerce Committee leaders, Maria Cantwell and Chuck Grassley, along with 12 lawmakers, are requesting an update from the Federal…
“Plan E”: A Proposal for a Universal Benefit for Cell and Gene Therapies
Cell and gene therapies (CGTs) have provided new optimism for patients living with diseases previously considered untreatable. These groundbreaking treatments…
Aimed Alliance Release New Resources on PDABs
On January 22, 2024, Aimed Alliance published two new resources on prescription drug affordability boards (PDABs). These boards, established at…
FDA Authorizes Florida’s Drug Importation Program
On January 5, 2024, the U.S. Food and Drug Administration (FDA) approved Florida’s Agency for Health Care Administration drug importation…
CBO Responds to Calls from the House Budget Committee to Consider New Data on IRA Impact on Innovation
Responding to inquiries from the House Budget Committee, the Congressional Budget Office (CBO) has signaled its openness to examining new…
New Report Highlights Value of Treatments to Patients
A recent report by the Alliance for Patient Access (AfPA) titled “At What Price? Medication Value, Patient Care & the…
GOA Finds Rebates Do Not Lower Consumer Costs
A recent report by the Government Accountability Office found that despite the substantial rebates private plans received for Medicare Part…